Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANTE: De-escalation and treatment-free remission with nilotinib then nilotinib + asciminib in CML
2024-516122-66-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib and asciminib in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: Primary: Molecular remission at 96 weeks after start of consolidation (TFR1) and 48 weeks after start of TFR2. Started Jan 2019; status: completed.
02
Drugs
nilotinibasciminib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-516122-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516122-66-00.